3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Prostatic Neoplasms
9
Breast Neoplasms
7
Obesity
4
Colorectal Neoplasms
4
Rectal Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Sarcoma
2
Radiation Injuries
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Weight Loss
1
Uterine Cervical Dysplasia
1
Stage IV Breast Cancer AJCC v6 and v7
1
Sezary Syndrome
1
Sexuality
1
Sexual Dysfunction, Physiological
1
Prostate Adenocarcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Peritoneal Neoplasms
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Patient Compliance
1
Overweight
1
Neuroendocrine Tumors
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Interventions
Temozolomide
88
Bevacizumab
49
Radiotherapy
36
Irinotecan
22
Magnetic Resonance Spectroscopy
21
Surgical Procedures, Operative
17
Carboplatin
17
Carmustine
15
Radiation
13
Nivolumab
11
IL13-PE38
8
Erlotinib Hydrochloride
8
Thalidomide
7
Radiotherapy, Intensity-Modulated
7
Lomustine
7
Imatinib Mesylate
7
Everolimus
7
Aminolevulinic Acid
7
sargramostim
6
Topotecan
6
O(6)-benzylguanine
6
Cyclophosphamide
6
Chemotherapy, Adjuvant
6
vandetanib
5
temsirolimus
5
fluorodopa F 18
5
Vincristine
5
Surveys and Questionnaires
5
Radiosurgery
5
Flucytosine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Glioma
×
Diet Therapy
×
Clear all
NCT02286167
2026-03-24
GLAD
Wake Forest University Health Sciences
Phase NA
Completed
25 enrolled